Briefs from primary sources
The stream
Two-sentence briefs on FDA announcements, Federal Register documents and ClinicalTrials.gov records, each linked to its source.
Machine-summarized from primary sources; not independently reported. How we use automation
Monday, November 16, 2026
-
CMS reports FY 2026 improper payment rates below 10% threshold
CMS estimates Original Medicare improper payment rate at 7.32%, or $33.96 billion, down from 6.55%, or $28.83 billion in FY 2025. Medicare Part C, Part D, Medicaid, CHIP and APTC rates also decline, with most improper payments due to insufficient documentation.
Source: CMS fact sheet, November 16, 2026
-
FDA approves giredestrant with everolimus for ESR1-mutated breast cancer
On November 16, 2026 the FDA approved giredestrant (Wilserdly) in combination with everolimus for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. The approval includes the FoundationOne Liquid CDx assay as a companion diagnostic to identify ESR1 mutations.
Source: FDA approval notification, November 16, 2026
-
AmyriAD acquires AD04 Alzheimer's program from ADvantage
AmyriAD announced the acquisition of the AD04 program, a Phase 2b-ready investigational drug targeting neuroinflammation in mild Alzheimer's disease. The program was derived from a 332-patient Phase 2 vaccine study and is planned to enter Phase 2b development under the Innovative Licensing and Access Pathway.
Source: Company press release (PR Newswire), November 16, 2026
-
Dexa Medica Group registers completed Phase 3 trial of DLBS3233 in prediabetes
The study enrolled 120 participants and was first posted on ClinicalTrials.gov on November 16, 2026. It compared DLBS3233 at 100 mg and 200 mg once daily to Metformin XR 500 mg twice daily over a 12-week course of therapy.
Source: ClinicalTrials.gov registry record, November 16, 2026
-
Novartis registers Phase 3 trial of Pacibekitug in patients after a Myocardial Infarction
The study, PINNACLE-MI, plans to enroll 10,000 participants and aims to demonstrate superiority of Pacibekitug over placebo in reducing 3-point coronary major adverse cardiovascular events in participants after a Myocardial Infarction. It is scheduled to start on November 30, 2026, with primary completion expected on October 22, 2030.
Source: ClinicalTrials.gov registry record, November 16, 2026
-
AstraZeneca posts results of L-MOCA olaparib maintenance trial
The company posted first results for its Phase 3 L-MOCA study, enrolling 225 participants who received olaparib 300mg tablets as maintenance therapy after platinum-based chemotherapy. The trial, which began on May 29, 2018, completed primary data collection on January 27, 2025.
Source: ClinicalTrials.gov results record, November 16, 2026
-
Novo Nordisk posts results of Phase 3 dasiglucagon vs glucagon study in Asian adults with T1D
The study, completed with 38 participants, compared dasiglucagon and glucagon for treating severe hypoglycaemia in Asian adults with type 1 diabetes. Results were first posted on ClinicalTrials.gov on November 16, 2026.
Source: ClinicalTrials.gov results record, November 16, 2026
-
Novo Nordisk posts results of Phase 3 liraglutide trial in children with obesity
Results for the 56-week, double-blind, randomized, placebo-controlled trial were first posted on ClinicalTrials.gov on November 16, 2026. The study enrolled 82 children aged 6 to below 12 years to evaluate the effect and safety of liraglutide 3.0 mg on weight management.
Source: ClinicalTrials.gov results record, November 16, 2026
-
Roche Diagnostics makes Endotrophin research prototype assay available on cobas e801
The assay, a sandwich immunoassay, quantifies the intact 77-amino-acid Endotrophin hormone at Nordic Bioscience's CLIA lab. It has been measured in more than 50,000 patients with cardio-kidney-metabolic disease.
Source: Company press release (PR Newswire), November 16, 2026
-
Ribupatide shows significant weight loss in adults without diabetes
In a phase 3 trial of 567 participants, once-weekly ribupatide produced least-squares mean weight reductions of -10.7%, -16.4%, and -17.7% at 48 weeks for 2, 4, and 6 mg doses versus -1.4% with placebo. Gastrointestinal events were the most frequent adverse events, occurring in 47.9%, 58.2%, and 63.1% of participants at the three doses.
Source: PubMed record of a Phase III journal article, November 16, 2026
Saturday, November 14, 2026
-
Lilly presents new data on Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026
Lilly will present Phase 2 data showing EloraTZP achieved an average weight loss of 54.1 lbs (23.3%) and lowered A1C by 2.9% in adults with obesity or overweight and type 2 diabetes. Retatrutide results from TRIUMPH trials demonstrated reductions in apnea-hypopnea index and knee osteoarthritis pain up to 36.1 events per hour and 4.5 points, respectively.
Source: Company press release (PR Newswire), November 14, 2026
Friday, November 13, 2026
-
CMS announces optional hold harmless period for Medicaid work requirement
CMS said the optional hold harmless period runs through June 30, 2027, giving states a transition period to modernize systems and improve the beneficiary experience. States that implement the hold harmless period will assess whether individuals meet the work requirement or are excluded from it, but they will not deny applications or disenroll otherwise eligible individuals solely for failure to meet the requirement.
Source: CMS press release, November 13, 2026
-
FDA approves first drug to treat adults with primary membranous nephropathy
The FDA approved Gazyva (obinutuzumab) injection for adults with primary membranous nephropathy at risk of disease progression to induce remission of proteinuria. In the MAJESTY Phase 3 study, 36% of patients achieved complete remission at week 104 versus 6% with tacrolimus.
Source: FDA approval notification, November 13, 2026
-
FDA approves durvalumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer
On November 13, 2026, the FDA approved durvalumab (Imfinzi, AstraZeneca) in combination with enfortumab vedotin-ejfv as neoadjuvant treatment followed by single-agent durvalumab as adjuvant therapy after radical cystectomy for adult patients with muscle invasive bladder cancer who are ineligible for or have refused cisplatin-based chemotherapy. The approval was granted under priority review and six weeks ahead of the FDA goal date.
Source: FDA approval notification, November 13, 2026
-
Novatek registers Phase 2/3 trial of NP-101 in GEP-NECs
The study, led by Novatek Pharmaceuticals, plans to enroll an estimate of 381 participants to evaluate the safety and efficacy of NP-101 combined with Nivolumab and Ipilimumab versus placebo in refractory advanced and metastatic gastroenteropancreatic neuroendocrine carcinomas. It is planned to begin in January 2027 and reach primary completion in December 2029.
Source: ClinicalTrials.gov registry record, November 13, 2026
-
AstraZeneca registers Phase 3 trial of Symbicort Aerosphere in children
The study plans to enroll 216 participants aged 4 to <12 years and start on October 30, 2026. It plans to compare BFF MDI 80/4.8 μg 2 actuations BID to BD MDI 80 μg 2 actuations BID over 6 weeks to assess lung function and safety.
Source: ClinicalTrials.gov registry record, November 13, 2026
-
RemeGen registers Phase IIIb trial of RC28-E Injection in DME and wAMD
The study, led by RemeGen Co., Ltd., plans to enroll 350 participants and has a planned start date of October 30, 2026. It aims to evaluate the safety profile and explore the efficacy of RC28-E in participants with diabetic macular edema and wet age-related macular degeneration.
Source: ClinicalTrials.gov registry record, November 13, 2026
-
RemeGen registers Phase II/III study of RC118 plus RC148 for claudin 18.2-positive gastric cancer
The study, led by RemeGen Co., Ltd., plans to enroll 680 participants and plans to start in November 2026, with primary completion projected for April 30, 2030. It compares RC118/RC148 combinations to Tislelizumab plus CAPOX as first-line therapy for HER2-negative, claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma.
Source: ClinicalTrials.gov registry record, November 13, 2026
-
Janssen posts results of Phase 3 seltorexant trial in major depressive disorder with insomnia
The study enrolled 757 participants and began on September 15, 2020, with primary completion on October 3, 2023. It compared seltorexant 20 mg to quetiapine XR as adjunctive therapy to antidepressants in adults and elderly patients with major depressive disorder with insomnia symptoms who had responded inadequately to antidepressant therapy.
Source: ClinicalTrials.gov results record, November 13, 2026
-
AbbVie posts results of Phase 3b TRITON study of Bimatoprost SR in glaucoma
The trial enrolled 515 participants and completed primary data collection on August 8, 2025. It evaluated the duration of intraocular pressure-lowering effect and safety of as-needed Bimatoprost SR in participants with open-angle glaucoma or ocular hypertension not adequately managed with topical IOP-lowering medication.
Source: ClinicalTrials.gov results record, November 13, 2026
-
Harmony Biosciences posts results of Phase 3 pitolisant study in idiopathic hypersomnia
Results for the open-label study were first posted on ClinicalTrials.gov on November 13, 2026. The completed study enrolled 119 participants and assessed the long-term safety and effectiveness of pitolisant after the double-blind randomized withdrawal phase of HBS-101-CL-010.
Source: ClinicalTrials.gov results record, November 13, 2026
-
Authors find no link between engraftment microbiome diversity and non-relapse mortality
The authors of a Phase III trial published in Nature Medicine reported no association between engraftment microbiome diversity and non-relapse mortality after 1 year (P = 0.314). They also found that lower baseline microbiome diversity was associated with shorter overall survival (P = 0.007).
Source: PubMed record of a Phase III journal article, November 13, 2026
-
EMA recommends approval of seven new medicines at CHMP meeting
The Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization for Aumseqa, Baxfendy, Zybrivo, Garzulys, Donrafylix, Fondaparinux sodium Evumed, and Ruxolitinib Krka. The recommendations cover treatments for non-small cell lung cancer, hypertension, non-squamous non-small cell lung cancer, diabetes, venous thromboembolism, and myelofibrosis, among others.
Source: EMA news release, November 13, 2026
-
CHMP adopts positive opinion on Zybrivo for non-squamous NSCLC
On 12 November 2026 the CHMP recommended granting a marketing authorization for Zybrivo, a sintilimab-based therapy, for first-line treatment of adult non-squamous non-small cell lung cancer. The recommendation follows a randomised, multicentre, double-blind, placebo-controlled study showing improved progression-free survival when sintilimab is combined with chemotherapy.
Source: EMA medicine page (CHMP opinion), November 13, 2026
-
CHMP recommends marketing authorization for Ruxolitinib Krka
On 12 November 2026 the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for Ruxolitinib Krka, intended for the treatment of myelofibrosis, polycythaemia vera and graft-versus-host disease. The generic will be available as 5 mg, 10 mg, 15 mg and 20 mg tablets.
Source: EMA medicine page (CHMP opinion), November 13, 2026
-
CHMP adopts positive opinion on Fondaparinux sodium Evumed
On 12 November 2026 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a marketing authorization for Fondaparinux sodium Evumed, a generic of Arixtra. The product is intended for prevention of venous thromboembolic events in adults undergoing major orthopaedic or abdominal surgery, immobilised patients, and for treatment of unstable angina, myocardial infarction, superficial-vein thrombosis, deep-vein thrombosis and pulmonary embolism.
Source: EMA medicine page (CHMP opinion), November 13, 2026
-
CHMP adopts positive opinion on Donrafylix
On 12 November 2026 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorization for Donrafylix, a biosimilar insulin aspart intended for the treatment of diabetes mellitus. The applicant is Kuraci BV and Donrafylix will be available as a 100 units/ml solution for injection.
Source: EMA medicine page (CHMP opinion), November 13, 2026
-
CHMP adopts positive opinion on Baxfendy
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on 12 November 2026, recommending marketing authorization for Baxfendy, a baxdrostat tablet for uncontrolled hypertension. The opinion was issued by the EMA for AstraZeneca AB.
Source: EMA medicine page (CHMP opinion), November 13, 2026
-
CHMP adopts positive opinion on Aumseqa
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a marketing authorization for Aumseqa, a 55 mg film-coated tablet intended for first-line treatment of adult patients with advanced NSCLC harbouring EGFR exon 19 deletions or L858R mutations, and for treatment of EGFR T790M mutation-positive NSCLC. The applicant for the medicinal product is SFL Pharmaceuticals Deutschland GmbH.
Source: EMA medicine page (CHMP opinion), November 13, 2026
Thursday, November 12, 2026
-
Amyris to acquire sweet protein innovator Oobli
Amyris, Inc. announced it will acquire Oobli, a leading sweet protein innovator, to add a proven protein technology platform to its biomanufacturing capabilities. The acquisition is expected to close in the coming weeks, with all existing customer commitments and brand partnerships honored uninterrupted.
Source: Company press release (PR Newswire), November 12, 2026
-
PAI pharma acquires nexus pharmaceuticals expanding sterile injectable portfolio
PAI pharma announced the acquisition of nexus pharmaceuticals, adding an established commercial portfolio of over 20 hospital injectable products. The deal builds on PAI's investment in domestic sterile manufacturing and expands its hospital-focused pharmaceutical portfolio.
Source: Company press release (PR Newswire), November 12, 2026
-
Olympus announces CMS valuation and reimbursement rates for new ESD CPT codes
Olympus said the U.S. Centers for Medicare & Medicaid Services published final valuations and CY2027 Medicare reimbursement rates for two new Category I CPT codes, CPT 43498 for upper gastrointestinal ESD and CPT 45991 for lower gastrointestinal ESD, effective Jan. 1, 2027. The company noted the rates reflect the clinical complexity and physician work involved in ESD.
Source: Company press release (PR Newswire), November 12, 2026
-
Orphalan expands TRADITiONAL study into China, first participant randomised worldwide
Orphalan SA announced the expansion of its Phase 3 TRADITiONAL Study into China, marking the first participant worldwide randomised at The Second Affiliated Hospital of Zhejiang University School of Medicine. The study evaluates once-daily trientine tetrahydrochloride versus D-penicillamine over 48 weeks.
Source: Company press release (PR Newswire), November 12, 2026
-
Cold Spring Harbor Laboratory hosts 21st Double Helix Medals dinner
The 21st annual Double Helix Medals dinner raised $6.5 million for CSHL's biological research and education programs. The event honored Dr. Kevin J. Tracey and philanthropist Michael Milken.
Source: Company press release (PR Newswire), November 12, 2026
-
AbbVie registers Phase 2b/3 study of ABBV-2294 in systemic sclerosis
The study plans to enroll 580 participants at about 200 sites worldwide, with a planned start date of December 11, 2026. It plans to evaluate the safety and efficacy of the combination of ABBV-722 and upadacitinib versus placebo over 52 weeks with optional extension periods.
Source: ClinicalTrials.gov registry record, November 12, 2026
-
Pfizer registers Phase 3 trial of berobenatide in women with stress urinary incontinence and obesity
The study, titled VESPER-SUI, plans to enroll 900 participants and has a planned start date of November 17, 2026. It aims to learn about the safety and effectiveness of berobenatide in adult women with stress urinary incontinence and obesity or overweight.
Source: ClinicalTrials.gov registry record, November 12, 2026
-
Telix registers Phase 3 study of [18F]FET PET in brain metastases
The study, led by Telix Pharmaceuticals (Innovations) Pty Limited, plans to enroll 381 participants and begin in December 2026. It will evaluate whether [18F]Floretyrosine PET can differentiate tumor progression from treatment-related changes in patients with brain metastases and equivocal MRI findings.
Source: ClinicalTrials.gov registry record, November 12, 2026
-
Qilu Pharmaceutical registers Phase 3 trial of QLS4131 in relapsed or refractory multiple myeloma
The study, first posted on ClinicalTrials.gov on November 12, 2026, plans to enroll 300 participants and has a planned start date of December 30, 2026. It compares QLS4131 injection with the investigator's choice regimen in participants with relapsed or refractory multiple myeloma.
Source: ClinicalTrials.gov registry record, November 12, 2026
-
AstraZeneca registers Phase III trial of FDC laroprovstat/rosuvastatin in hypercholesterolemia
The study plans to enroll 204 participants and is expected to start on December 21, 2026. It aims to evaluate the effect on LDL-C and the safety and tolerability of the fixed-dose combination in lipid-lowering treatment-naïve patients.
Source: ClinicalTrials.gov registry record, November 12, 2026
-
Rhythm posts results of Phase 3 setmelanotide trial in genetic obesity
The study enrolled 296 participants and completed primary data collection on December 19, 2025. Results were first posted on ClinicalTrials.gov on November 12, 2026.
Source: ClinicalTrials.gov results record, November 12, 2026
-
Hoffmann-La Roche posts results of Phase III obinutuzumab study in systemic lupus erythematosus
Results for the study were first posted on ClinicalTrials.gov on November 12, 2026. The Phase III trial enrolled 303 participants, with primary completion on September 15, 2025, and compared obinutuzumab to placebo in patients with active, autoantibody-positive systemic lupus erythematosus receiving standard-of-care therapy.
Source: ClinicalTrials.gov results record, November 12, 2026
-
Pfizer posts results of Phase 3 gene therapy study in Duchenne Muscular Dystrophy
The study, a Phase 3 long-term safety and efficacy follow-up of fordadistrogene movaparvovec, enrolled 7 participants and was terminated. It began on March 13, 2023, with primary completion on September 24, 2025.
Source: ClinicalTrials.gov results record, November 12, 2026
Wednesday, November 11, 2026
-
Argá Medtech completes enrollment of paroxysmal AF cohort in COHERENT-AF
The company announced that 150 intention-to-treat subjects were enrolled in the paroxysmal atrial fibrillation cohort across 27 sites in Europe and the United States. Enrollment of the persistent AF cohort is ongoing and expected to finish in the next two months.
Source: Company press release (PR Newswire), November 11, 2026
-
Lilly reports 52-week results of Taltz and Zepbound in psoriatic arthritis and obesity
The company said that at one year 43.7% of patients receiving Taltz and Zepbound achieved ACR50 compared with 15.7% for Taltz alone. The 52-week Phase 3b study randomized 271 participants 1:1 to the combination or Taltz monotherapy and reported mild to moderate adverse events consistent with each drug's known safety profile.
Source: Company press release (PR Newswire), November 11, 2026
-
Zinzino acquires Uzesta to boost distribution capabilities in the APAC region
Zinzino has acquired the rights to Uzesta Global LLC's distributor database, inventory and intellectual property rights through subsidiaries in Taiwan, Hong Kong and Thailand. The deal includes a fixed purchase price of 0.8 mUSD in cash and a deferred price of 0.4 mUSD, with potential additional payments up to 6.0 mUSD based on future sales.
Source: Company press release (PR Newswire), November 11, 2026
-
Amgen announces positive Phase 3 results for dazodalibep in Sjögren's disease
Amgen said the Phase 3 OASIZ-301 study met its primary endpoint, with both 1,500 mg every four weeks and 3,000 mg every 12 weeks regimens showing statistically significant reductions in ESSDAI score versus placebo at Week 48. The company noted improvements in patient-reported dryness and that the most common adverse events were nasopharyngitis, urinary tract infection, hypertension and infusion-related reactions.
Source: Company press release (PR Newswire), November 11, 2026
-
Xtalks hosts webinar on using EHR and applied AI to speed patient recruitment
The webinar, scheduled for Wednesday, December 2, 2026 at 10am EST, explores how integrating EHR capabilities with applied AI can improve patient identification and reduce manual record review. Speakers include Mike Margiotta of AiSync, Meagan Garvin of Trialbee, and Carl Wolff of Trialbee.
Source: Company press release (PR Newswire), November 11, 2026
-
FDA releases draft guidance on early-phase IND protocols for solid tumors
FDA announced the availability of a draft guidance titled "Early-Phase IND Protocol Recommendations for Solid Tumors" to provide recommendations for sponsors and investigators developing early-phase trials. Comments are due by January 11, 2027, and the guidance covers first-in-human protocols for drugs and biologic products with limited human experience, but does not address hematologic malignancies.
Source: Federal Register notice, November 12, 2026
-
Abbisko's PIMJETMI receives U.S. FDA approval for TGCT
The U.S. FDA approved PIMJETMI as a systemic treatment for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitation or severe morbidity. The approval follows earlier approvals in China, Canada and Switzerland and is based on the Phase III MANEUVER study showing a 56% objective response rate versus 3% for placebo.
Source: Company press release (PR Newswire), November 10, 2026
Tuesday, November 10, 2026
-
NEB and Mammoth Biosciences launch MB-CasFire enzyme for one-pot isothermal assays
NEB will manufacture and globally distribute Mammoth Biosciences' proprietary MB-CasFire enzyme, a thermostable Type V CRISPR nuclease that works across 37-65 °C and can be coupled directly with LAMP, RPA and NEAR assays. MB-CasFire resolves targets at single-nucleotide resolution and simplifies assay architecture by eliminating the need for multiple temperature incubations or component additions.
Source: Company press release (PR Newswire), November 10, 2026
-
FDA approves pimicotinib for symptomatic tenosynovial giant cell tumor
On November 10, 2026, the FDA approved pimicotinib (Pimjetmi, EMD Serono, Inc.) for adults with symptomatic TGCT for whom surgical resection may cause worsening functional limitation or severe morbidity. The approval follows a double-blind, randomized, placebo-controlled MANEUVER trial that evaluated pimicotinib 50 mg once daily.
Source: FDA approval notification, November 10, 2026
-
Eli Lilly launches Life Doesn't Slow Down campaign for Foundayo
The company announced a new campaign encouraging patients to discuss weight-loss options with doctors. The campaign highlights Foundayo, a GLP-1 pill approved by the FDA in April 2026, and features comedian Leanne Morgan as a spokesperson.
Source: Company press release (PR Newswire), November 10, 2026
-
IMVIONIX acquires U.S. and Canadian rights to BEOVU
IMVIONIX Inc. announced it has acquired exclusive commercial rights to BEOVU (brolucizumab-dbll) in the United States and Canada from Novartis, marking the company's official commercial launch. BEOVU is FDA-approved for treating neovascular (wet) age-related macular degeneration and diabetic macular edema.
Source: Company press release (PR Newswire), November 10, 2026
-
ISTx registers Phase 3 trial of ceftobiprole in pediatric Staphylococcus aureus bacteremia
The study, led by ISTx, LLC, plans to enroll 60 participants and begin on October 30, 2026, to compare ceftobiprole with standard-of-care antibiotics in children under 18 with Staphylococcus aureus bacteremia, including right-sided infective endocarditis. The trial will also evaluate safety, tolerability, efficacy, and pharmacokinetics of ceftobiprole.
Source: ClinicalTrials.gov registry record, November 10, 2026
-
Sanofi registers Phase 3 trial of venglustat vs Cerezyme in pediatric Gaucher disease type 3
The study, titled LEAP2KIDS, plans to enroll 18 pediatric participants aged 2 to 11 years with Gaucher Disease Type III who have reached therapeutic goals with enzyme replacement therapy. It is a randomized, open-label, active-comparator trial with a 52-week primary analysis period and a 52-week extended treatment period.
Source: ClinicalTrials.gov registry record, November 10, 2026
-
Boehringer Ingelheim registers Phase 3 safety rollover trial of obrixtamig in advanced cancer
The study, first posted on ClinicalTrials.gov on November 10, 2026, plans to enroll 68 participants and begin in March 2027. It plans to find out how well participants who received obrixtamig in a previous study tolerate the drug.
Source: ClinicalTrials.gov registry record, November 10, 2026
-
Apellis posts results of Pegcetacoplan long-term safety extension study
The study, completed on September 4, 2025, enrolled 137 participants who had previously completed a pegcetacoplan study. It was an open-label, non-randomized, multi-center Phase 3 extension study evaluating long-term safety and efficacy in PNH.
Source: ClinicalTrials.gov results record, November 10, 2026
-
Alcon posts results of Phase 3 FID 123320 study
The study enrolled 284 participants and was completed with results first posted on ClinicalTrials.gov on November 10, 2026. It assessed the safety and efficacy of FID 123320 Ophthalmic Solution (Apraclonidine HCl 0.125%) versus vehicle for relieving ocular redness in pediatric and adult populations.
Source: ClinicalTrials.gov results record, November 10, 2026
-
Genmab posts results of Phase 3 epcoritamab trial in relapsed/refractory DLBCL in China
Results for the study were first posted on ClinicalTrials.gov on November 10, 2026. The trial enrolled 72 participants who were randomized to receive epcoritamab or investigator's choice chemotherapy for relapsed/refractory diffuse large B-cell lymphoma.
Source: ClinicalTrials.gov results record, November 10, 2026
-
Alcon posts results of Phase 3 apraclonidine study for ocular redness
The study enrolled 159 participants and was completed on November 14, 2024. Results were first posted on ClinicalTrials.gov on November 10, 2026.
Source: ClinicalTrials.gov results record, November 10, 2026